Lineage Cell Therapeutics Inc (LCTX) Actualités

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked...

Form 8-K - Current report

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for...

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for...